Barclays
SLGC

Barclays’s SomaLogic, Inc. Class A Common Stock SLGC Stock Holding History

Barclays’s Portfolio SLGC Stock Details SLGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,745,920
Closed -$6.95M – 5484
2023
Q4 		$6.95M Buy
2,745,920
+149,131
+6% +$347K ﹤0.01% 1819
2023
Q3 		$6.21M Buy
2,596,789
+20,853
+0.8% +$46.2K ﹤0.01% 1204
2023
Q2 		$5.95M Sell
2,575,936
-32,645
-1% -$92.2K ﹤0.01% 1253
2023
Q1 		$6.65M Buy
2,608,581
+98,322
+4% +$282K ﹤0.01% 1372
2022
Q4 		$6.3M Buy
2,510,259
+2,485,878
+10,196% +$6.94M ﹤0.01% 1461
2022
Q3 		$70K Sell
24,381
-607,066
-96% -$2.56M ﹤0.01% 3677
2022
Q2 		$2.85M Buy
631,447
+630,778
+94,287% +$3.75M ﹤0.01% 1630
2022
Q1 		$5K Buy
+669
New +$5.9K ﹤0.01% 4706

Barclays's SLGC Position: Q1 2024 in Review

Barclays sold out of SomaLogic, Inc. Class A Common Stock (SLGC) in Q1 2024, closing a stake of 2,745,920 shares — an estimated $6.95M sold.

Barclays first reported a position in SLGC in Q1 2022 and held it in 8 quarters. The position peaked at $6.95M in Q4 2023. 0 funds tracked by Wall St. Rank hold SLGC as of Q1 2024.

  • Barclays reported no remaining SomaLogic, Inc. Class A Common Stock position as of Q1 2024 after selling out during the quarter.
  • Barclays sold 2,745,920 SomaLogic, Inc. Class A Common Stock shares in Q1 2024, an estimated $6.95M.
  • Barclays first reported a position in SomaLogic, Inc. Class A Common Stock in Q1 2022 and held it in 8 quarters.
  • Barclays's SomaLogic, Inc. Class A Common Stock position peaked at $6.95M in Q4 2023.
  • 0 funds tracked by Wall St. Rank held SomaLogic, Inc. Class A Common Stock as of Q1 2024.

Based on Barclays's 13F filing for Q1 2024, filed 15 May 2024.